NO2209805T3 - - Google Patents
Info
- Publication number
- NO2209805T3 NO2209805T3 NO08844563A NO08844563A NO2209805T3 NO 2209805 T3 NO2209805 T3 NO 2209805T3 NO 08844563 A NO08844563 A NO 08844563A NO 08844563 A NO08844563 A NO 08844563A NO 2209805 T3 NO2209805 T3 NO 2209805T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98360607P | 2007-10-30 | 2007-10-30 | |
| PCT/EP2008/009070 WO2009056268A1 (en) | 2007-10-30 | 2008-10-27 | An antigen associated with rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2209805T3 true NO2209805T3 (https=) | 2018-02-03 |
Family
ID=40282320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO08844563A NO2209805T3 (https=) | 2007-10-30 | 2008-10-27 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8222377B2 (https=) |
| EP (3) | EP3281952B1 (https=) |
| JP (3) | JP5106635B2 (https=) |
| KR (3) | KR101608544B1 (https=) |
| CN (2) | CN103396483B (https=) |
| AU (1) | AU2008317941B2 (https=) |
| BR (1) | BRPI0818272B8 (https=) |
| CA (1) | CA2704296C (https=) |
| DK (2) | DK3281952T3 (https=) |
| ES (2) | ES2646228T3 (https=) |
| HU (2) | HUE050038T2 (https=) |
| MX (1) | MX2010004726A (https=) |
| NO (1) | NO2209805T3 (https=) |
| PL (2) | PL2209805T3 (https=) |
| PT (2) | PT3281952T (https=) |
| RU (2) | RU2486198C2 (https=) |
| SI (2) | SI2209805T1 (https=) |
| WO (1) | WO2009056268A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070084556A1 (en) | 2005-10-14 | 2007-04-19 | Langseder Neal E | Method of applying a label to a squeeze tube |
| WO2008120101A2 (en) * | 2007-04-02 | 2008-10-09 | Philogen S.P.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| DK3281952T3 (da) | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| CA2748401C (en) | 2009-01-07 | 2017-09-12 | Philogen S.P.A. | Antigens associated with endometriosis |
| EP2461832B1 (en) | 2009-08-05 | 2017-06-28 | Philogen S.p.A. | Targeting of bone marrow neovasculature |
| ES2872964T3 (es) * | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| PE20150645A1 (es) * | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
| TWI499426B (zh) * | 2012-09-27 | 2015-09-11 | Philogen Spa | 與發炎性腸病有關之抗原 |
| ES2743423T3 (es) | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| CR20180087A (es) | 2015-07-16 | 2018-05-14 | Philogen Spa | Inmunoconjugados de il22 |
| US20190309060A1 (en) | 2016-01-15 | 2019-10-10 | Philogen S.P.A. | Intestinal antigens for pharmacodelivery applications |
| CN110997718B (zh) | 2017-06-07 | 2023-11-10 | 菲洛根股份公司 | 血管内皮生长因子/抗纤连蛋白抗体融合蛋白 |
| JP2017197558A (ja) * | 2017-06-07 | 2017-11-02 | フィロゲン エスピーエー | 炎症性腸疾患に関連する抗原 |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CN121652287A (zh) * | 2019-03-06 | 2026-03-13 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| CA3186753A1 (en) | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| EP4185615A1 (en) | 2020-07-22 | 2023-05-31 | Philogen S.p.A. | Treatment of pulmonary hypertension |
| CN113480636B (zh) * | 2021-06-23 | 2023-11-03 | 烟台科瑞斯生物技术有限责任公司 | 重组人纤连蛋白及其制备、活性测定和稳定性实验方法 |
| WO2023175077A1 (en) | 2022-03-17 | 2023-09-21 | Philogen S.P.A | Anti-ed-a antibodies for the treatment of pulmonary hypertension |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| US5420012A (en) * | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| WO1992017604A1 (fr) * | 1991-03-26 | 1992-10-15 | Otsuka Pharmaceutical Factory, Inc. | Anticorps monoclonal anti-eda |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| AU6098994A (en) | 1993-01-27 | 1994-08-15 | Duke University | Methods and agents for the diagnosis and treatment of rheumatoid arthritis |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| DK1137941T4 (da) | 1998-12-10 | 2014-01-06 | Brystol Myers Squibb Company | Protein-scaffolds til antistof-mimetika og andre bindingsproteiner |
| AU2001239470A1 (en) | 2000-02-24 | 2001-09-03 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| WO2001076630A1 (en) * | 2000-04-06 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Diagnostics and remedies for rheumatoid arthritis |
| WO2001083816A2 (en) | 2000-05-04 | 2001-11-08 | Philogen S.R.L. | Method for detecting tumors |
| CN1246333C (zh) | 2000-09-07 | 2006-03-22 | 舍林股份公司 | EDb－纤粘连蛋白结构域(II)的受体 |
| US6780594B2 (en) * | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| US20020187100A1 (en) | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
| EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| AU2003238284A1 (en) | 2002-06-21 | 2004-01-06 | Duke University | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma |
| CN101972478B (zh) * | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| US7560095B2 (en) | 2003-04-22 | 2009-07-14 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| WO2005009366A2 (en) | 2003-07-24 | 2005-02-03 | Cornell Research Foundation, Inc. | Restoring vascular function |
| EP1660519B1 (en) | 2003-07-29 | 2014-05-14 | Immunomedics, Inc. | Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule |
| EP1702069A2 (en) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| JP2008514900A (ja) * | 2004-07-30 | 2008-05-08 | アデザ・バイオメデイカル・コーポレイシヨン | 疾病および他の状態のマーカーとしての癌胎児性フィブロネクチンならびに癌胎児性フィブロネクチンの検出のための方法 |
| US7785591B2 (en) * | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| AU2005304031B2 (en) | 2004-11-09 | 2009-04-23 | Philogen Spa | Antibodies against tenascin-C |
| ES2388068T3 (es) * | 2004-12-23 | 2012-10-08 | Molmed Spa | Producto de conjugación |
| CA2607954A1 (en) * | 2005-05-11 | 2006-11-16 | Philogen S.P.A. | Conjugate for targeting of drug |
| AU2006262502A1 (en) | 2005-06-23 | 2007-01-04 | Emory Univerisity | Imaging agents |
| EP2015775B1 (en) | 2006-05-03 | 2011-06-01 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| CA2648484A1 (en) * | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
| WO2008120101A2 (en) * | 2007-04-02 | 2008-10-09 | Philogen S.P.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| EP2167541B1 (en) * | 2007-07-25 | 2012-12-19 | Philogen S.p.A. | The ed-a antigen of fibronectin is associated with the neovasculature of tumour metastases |
| DK3281952T3 (da) | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| CA2748401C (en) | 2009-01-07 | 2017-09-12 | Philogen S.P.A. | Antigens associated with endometriosis |
| US20110318302A1 (en) | 2009-01-07 | 2011-12-29 | Kathrin Schwager | Cancer Treatment |
| BR112013007160A2 (pt) | 2010-09-29 | 2016-06-14 | Philogen Spa | ligante tiazolidina para a conjugação de fármacos a anticorpos |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| ES2743423T3 (es) | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| WO2014174105A1 (en) | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| CA2910044A1 (en) | 2013-04-26 | 2014-10-30 | Philogen S.P.A. | Il4 conjugated to antibodies against extracellular matrix components |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-10-27 DK DK17189028.8T patent/DK3281952T3/da active
- 2008-10-27 CN CN201310233951.9A patent/CN103396483B/zh active Active
- 2008-10-27 PL PL08844563T patent/PL2209805T3/pl unknown
- 2008-10-27 WO PCT/EP2008/009070 patent/WO2009056268A1/en not_active Ceased
- 2008-10-27 HU HUE17189028A patent/HUE050038T2/hu unknown
- 2008-10-27 US US12/740,641 patent/US8222377B2/en active Active
- 2008-10-27 EP EP17189028.8A patent/EP3281952B1/en active Active
- 2008-10-27 RU RU2010121874/10A patent/RU2486198C2/ru active
- 2008-10-27 ES ES08844563.0T patent/ES2646228T3/es active Active
- 2008-10-27 PT PT171890288T patent/PT3281952T/pt unknown
- 2008-10-27 PT PT88445630T patent/PT2209805T/pt unknown
- 2008-10-27 JP JP2010531449A patent/JP5106635B2/ja active Active
- 2008-10-27 AU AU2008317941A patent/AU2008317941B2/en active Active
- 2008-10-27 DK DK08844563.0T patent/DK2209805T3/en active
- 2008-10-27 SI SI200831867T patent/SI2209805T1/sl unknown
- 2008-10-27 MX MX2010004726A patent/MX2010004726A/es active IP Right Grant
- 2008-10-27 NO NO08844563A patent/NO2209805T3/no unknown
- 2008-10-27 CA CA2704296A patent/CA2704296C/en active Active
- 2008-10-27 SI SI200832134T patent/SI3281952T1/sl unknown
- 2008-10-27 BR BRPI0818272A patent/BRPI0818272B8/pt active IP Right Grant
- 2008-10-27 KR KR1020107011773A patent/KR101608544B1/ko active Active
- 2008-10-27 KR KR1020187006283A patent/KR102002739B1/ko active Active
- 2008-10-27 KR KR1020167007916A patent/KR101836968B1/ko active Active
- 2008-10-27 CN CN2008801231862A patent/CN101918443B/zh active Active
- 2008-10-27 EP EP08844563.0A patent/EP2209805B1/en active Active
- 2008-10-27 HU HUE08844563A patent/HUE037036T2/hu unknown
- 2008-10-27 ES ES17189028T patent/ES2807753T3/es active Active
- 2008-10-27 EP EP20181520.6A patent/EP3783019A1/en not_active Withdrawn
- 2008-10-27 PL PL17189028T patent/PL3281952T3/pl unknown
-
2012
- 2012-06-05 US US13/489,123 patent/US9556257B2/en active Active
- 2012-10-02 JP JP2012219986A patent/JP6154594B2/ja active Active
-
2013
- 2013-04-09 RU RU2013115891A patent/RU2649368C2/ru active
-
2014
- 2014-10-15 JP JP2014210887A patent/JP6198703B2/ja active Active
-
2016
- 2016-12-15 US US15/380,167 patent/US10385121B2/en active Active
-
2019
- 2019-07-17 US US16/514,080 patent/US20190352384A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2209805T3 (https=) | ||
| CN300729704S (zh) | 首饰链(hy-an0035) | |
| CN300729597S (zh) | 食品包装袋(c) | |
| CN300856393S (zh) | 管接头(2) | |
| CN300852311S (zh) | 包装袋(蛮牛小子) | |
| CN300850430S (zh) | 仿真鱼饵(yrc04-8.5) | |
| CN300823583S (zh) | 玄关镜连玄关台(12400) | |
| CN300799797S (zh) | 床头(cp5910) | |
| CN300788767S (zh) | 打火机(8628) | |
| CN300785887S (zh) | 连裤袜(2) | |
| CN300769297S (zh) | 商品电子防盗器(eas) | |
| CN300768396S (zh) | 组合厅柜(601) | |
| CN300768007S (zh) | 拐杖(sb6004猎豹型) | |
| CN300729970S (zh) | 插座(南非标准) | |
| CN300728118S (zh) | 头框(t09148) | |
| CN300728248S (zh) | 加湿器（x120-1） | |
| CN300729882S (zh) | 金属轮毂(425) | |
| CN300729878S (zh) | 金属轮毂(462) | |
| CN300729829S (zh) | 轮胎(花纹278) | |
| CN300729740S (zh) | 花盆（珠点国际方盆） | |
| CN300726318S (zh) | 沙发(s329) | |
| CN300871234S (zh) | 展柜(主副) | |
| CN300729505S (zh) | 包装盒(彩图) | |
| CN300729611S (zh) | 包装袋(久津源茗茶) | |
| CN300728364S (zh) | 手电筒(ksl-0526) |